Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients
Authors:
- 6 July 2020
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 149 (1) , 65-71
Abstract
Introduction Tumor-related epilepsy may respond to chemotherapy. In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone. Seizure outcomes were not reported. Methods We performed an unplanned secondary analysis of this trial’s data. The trial design has been previously reported. Seizures were recorded by clinicians as adverse events and by patients in quality of life questionnaires. A Chi-square test of seizure rates between the two groups (α = 0.05) and a Kaplan–Meier estimator of time-to-first self-reported seizure were planned. Results Almost all patients were followed until they died. In the radiotherapy alone group, 68 patients (24%) had a documented or self-reported seizure versus 83 patients (30%) in the temozolomide plus radiotherapy group, Chi-square analysis showed no difference (p = 0.15). Patients receiving radiotherapy alone tended to develop seizures earlier than those receiving temozolomide plus radiotherapy (p = 0.054). Patients with seizures had shorter overall survival than those without seizures (hazard ratio 1.24, p = 0.02). Conclusions This study was not powered to detect differences in seizure outcomes, but temozolomide seemed to have minimal impact on seizure control in elderly patients with glioblastoma. Clinical Trial Registration: NCT00482677 2007-06-05.Keywords
This publication has 17 references indexed in Scilit:
- Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive studyNeuro-Oncology Practice, 2018
- Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaNew England Journal of Medicine, 2017
- Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trialsNeuro-Oncology, 2016
- Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomideJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Seizure Prognosis in Brain Tumors: New Insights and Evidence-Based ManagementThe Oncologist, 2014
- Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomasJournal of Neurosurgery, 2011
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomasAnnals of Oncology, 2003
- Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological responseAnnals of Oncology, 2003
- Incidence and Clinical Characterization of Unprovoked Seizures in Adults: A Prospective Population‐Based StudyEpilepsia, 1996